Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.51 |
| ▸ | FLT1 | P17948 | 4/20 | 0.51 |
| ▸ | FLT4 | P35916 | 4/20 | 0.51 |
| ▸ | SRC | P12931 | 4/20 | 0.49 |
| ▸ | ABL1 | P00519 | 3/20 | 0.49 |
| ▸ | ABL2 | P42684 | 3/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613120 | 0.89 | KDR (0.55) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5623005 | 0.85 | SCN9A (0.47) | KDRENPP1EHMT2NSD2 | |
| SCHEMBL7215157 | 0.84 | EGFR (0.48) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL4025116 | 0.83 | EHMT2 (0.52) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL4388862 | 0.82 | KIT (0.53) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL4388859 | 0.82 | KIT (0.53) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL5498950 | 0.80 | EHMT2 (0.54) | KDREGFRFGFR1FLT1EHMT2 | |
| SCHEMBL5218230 | 0.80 | EHMT2 (0.49) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL4380551 | 0.79 | EHMT2 (0.53) | KDREGFRFGFR1FLT1EHMT2 | |
| SCHEMBL4686452 | 0.79 | EHMT2 (0.61) | KDREHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | KDR 3/4885EGFR 500/4885FGFR1 159/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | KDR 4/4885EGFR 549/4885FGFR1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.